Mérieux Foundation event

Off target effects of vaccination

June 8-10, 2015 - Les Pensieres Center for Global Health, Veyrier-du-Lac (France)

Summary

The immunological landscape is changing dramatically. We have recently learned that immune memory can be re-educated, that innate immunity can have “memory”, that certain lymphocytes can exhibit innate-like responses and that vaccines may have broader specificities that vary with age and sex. Recent clinical, immunological and epidemiological studies show that vaccines can provide greater protection than their intended purpose.

The workshop is designed to not only advance the science of vaccinology, but also to raise the key question that if indeed the off-target effects are real and measurable, how could the world imagine using these vaccines for their previously unintended purposes, and what additional actions would be required.

Download the program

Download the report

Program

Day 1 Monday 8 June

Day 2 Tuesday 9 June

Day 3 Wednesday 10 June

17:45 - 18:20

Key-note address: Bacillus Calmette-Guérin immunotherapy for bladder cancer: overview of an “off-target” effect of BCG immunotherapy

Gary D. STEINBERG

Download presentation

Session 1 Off-target effects of vaccination: defining the concept-range of offtarget effects - Case studies

Stanley PLOTKIN

18:30 - 18:50

The WHO review of the non-specific effects of vaccination

Terry NOLAN
Download presentation

Session 1 Continued

08:30 - 08:50

Live vaccines and off-target effects: BCG and measles vaccines

Peter AABY
09:05 - 09:25

Inactivated vaccines and off-target effects: DTP and interaction between live and inactivated vaccines

Henrik RAVN
Download presentation

Session 2 Priorities and Implications

Jacques LOUIS

09:40 - 10:00

What would be required to provide convincing evidence of off-target effects of vaccination?

Stanley PLOTKIN
10:45 - 11:05

Requirements for new trials to examine off-target effects of vaccination

Paul FINE

Session 3 Basic biological mechanisms accounting for the off-target effects of vaccination

William WARREN

11:20 - 11:40

Epigenetic reprogramming by listeria monocytogenes

Melanie HAMON
Download presentation
11:55 - 12:15

Trained immunity: impact for non-specific effects of vaccination

Mihai NETEA
Download presentation
14:00 - 14:20

Ontogeny of the immune system : implications for the response to vaccination

Ofer LEVY
Download presentation
15:05 - 15:25

Long-term innate immune memory via effects on bone marrow progenitors

Helen GOODRIDGE
Download presentation
15:25 - 15:40

Detecting an immune signature of measles using Population Data

Michael MINA

Session 4 How should the next generation of clinical trial and epidemiological studies be designed to provide convincing evidence of off-target/nonspecific effects of vaccination?

Michael GREENBERG

16:10 - 16:30

How could the childhood immunization programme be optimized in low- and high-income countries taking into account both specific and off-target effects of vaccines?

Frank SHANN
16:45 - 17:05

Implications of beneficial off-target effects for upcoming eradication campains (measles and polio)

Ane FISKER
Download presentation
17:20 - 17:40

Vaccinations against smallpox and tuberculosis are associated with better long-term survival

Christine STABELL-BENN
Download presentation
17:45 - 18:05

Can trials in Africa study both off-target effects and determinants of severe morbidity/mortality?

Nelly AMENYOGBE
Download presentation

Session 4 Continued

08:30 - 08:50

Discovery and validation of homologous T cell epitopes in pathogens and humans: what implications for vaccines?

Annie de GROOT
Download presentation
08:30 - 08:50

Developing a new live pertussis vaccine with beneficial off-target effects

Natalie MIELCAREK
Download presentation

Session 5 Repurpose vaccines for off-target effects: the perspectives of donors, regulatory and public health authorities and industry

Paul FINE

10:45 - 11:05

Regulatory implications and challenges

Jesse GOODMAN
11:20 - 11:40

Open data, knowledge management and identification of new uses of old vaccines

Barend MONS
11:55 - 12:15

An industry perspective

Michel DEWILDE

Back